Mirati Therapeutics (MRTX) – Hot FDA News
-
Mirati Therapeutics (MRTX) Provides Update on Regulatory Review in EU of KRAZATI
-
Mirati Therapeutics (MRTX) Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO Does Not Meet Primary Endpoint
-
-
Back to MRTX Stock Lookup